| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27e1ea5f65e8f958e48f1a9d53fdbb45 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9ba8e85d3dfd542e921f1e8d14d777c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74ff25957f1b72f95148cb2261e843ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd90e59c72908362ff6d84938a9bfdef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad8656bdfc5f547984d943f5c98307fb |
| publicationDate |
2014-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014070767-A1 |
| titleOfInvention |
Predictive markers for polyamine inhibitor cancer therapies |
| abstract |
The present disclosure relates to therapeutic methods and medical uses comprising the identification and use of cancer marker surrogates for increased polyamine expression. These markers may be used to identify patients who may be treated for diseases and disorders that are susceptible to polyamine synthesis inhibitors, and they can also be used to monitor therapeutic responses when such agents are used. More specifically, reduced levels of let-7 miRNA and elevated levels of LIN28 and HMGA2 proteins were found to correlate with elevated levels of polyamines and may be used for predicting the efficacy of cancer therapy using an ornithine decarboxylase (ODC1) inhibitor such as eflornithine (DFMO), suitably in combination with an NSAID such as sulindac. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109196362-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021378999-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020236562-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017075576-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973790-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11529326-B2 |
| priorityDate |
2012-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |